When a patient on a stable transdermal estradiol regimen cannot fill her prescription because patches are on backorder, the prescriber faces a clinical decision: switch to an oral formulation (with a different risk profile), switch to a different delivery system the patient hasnt used before, or consider a compounded transdermal estradiol preparation that delivers the same active ingredient through the same route
So just imagine, and I don't think this is a good idea, but imagine if only pharmaceutical drug companies were allowed to make peptides
Correlation of Hyaluronic Acid (HA), Syndecan-1 (SDC-1), Heparan sulfate (HS) with early stage end organ dysfunction in Sepsis patients
Much of the regulatory fight has focused on which ingredients compounders should be allowed to use
5-Amino-1MQ occupies a particularly ambiguous regulatory space
If particles persist after 10 minutes of patient swirling, the vial may have been compromised
